Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0312032 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Takaya Yamamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Spinal Cord, Kidney Neoplasms, Radiotherapy, Image-Guided, Magnetic Resonance Imaging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical.
Abstract (Originalsprache)
Background and purpose This study aimed to investigate the intrafractional movement of the spinal cord and spinal canal during MR-guided online adaptive radiotherapy (MRgART) for kidney cancer. Materials and methods All patients who received stereotactic MRgART for kidney cancer between February 2022 and February 2024 were included in this study. Patients received 30–42 Gy in 3-fraction MRgART for kidney cancer using the Elekta Unity, which is equipped with a linear accelerator and a 1.5 Tesla MRI. MRI scans were performed at three points during each fraction: for online planning, position verification, and posttreatment assessment. The spinal cord was contoured from the upper edge of Th12 to the medullary cone, and the spinal canal was contoured from Th12 to L3, using the first MRI. These contours were adjusted to the second and third MR images via deformable image registration, and movements were measured. Margins were determined via the formula “1.3×Σ+0.5×σ” and 95% prediction intervals.
Results
A total of 22 patients (66 fractions) were analyzed. The median interval between the first and third MRI scans were 38 minutes. The mean ± standard deviation of the spinal cord movements after this interval were −0.01 ± 0.06 for the x-axis (right–left), 0.01 ± 0.14 for the y-axis (caudal–cranial), 0.07 ± 0.05 for the z-axis (posterior–anterior), and 0.15 ± 0.08 for the 3D distance, respectively. The correlation coefficients of the 3D distance between the spinal cord and the spinal canal was high (0.92). The calculated planning organ at risk volume margin for all directions was 0.11 cm for spinal cord. The 95% prediction intervals for the x-axis, y-axis, and z-axis were −0.11–0.09 cm, −0.23–0.25 cm and −0.14–0.03 cm, respectively.
Conclusions
Margins are necessary in MRgART to compensate for intrafractional movement and ensure safe treatment delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
ORCID-Profile: Takaya Yamamoto, Shohei Tanaka, Noriyoshi Takahashi, Rei Umezawa, Yu Suzuki, Keita Kishida, So Omata, Kazuya Takeda, Hinako Harada, Yoshiyuki Katsuta
Förderung
- Kaken Pharmaceutical
Zitieren
APA
Yamamoto, T., Tanaka, S., Takahashi, N., Umezawa, R., Suzuki, Y., Kishida, K., Omata, S., Takeda, K., Harada, H., Sato, K., Katsuta, Y., Kadoya, N., & Jingu, K. (2024). Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0312032
Vancouver
Yamamoto T, Tanaka S, Takahashi N, Umezawa R, Suzuki Y, Kishida K, et al. Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0312032
BibTeX
@article{Yamamoto2024,
author = {Yamamoto, Takaya and Tanaka, Shohei and Takahashi, Noriyoshi and Umezawa, Rei and Suzuki, Yu and Kishida, Keita and Omata, So and Takeda, Kazuya and Harada, Hinako and Sato, Kiyokazu and Katsuta, Yoshiyuki and Kadoya, Noriyuki and Jingu, Keiichi},
title = {Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0312032}
}
EUVIMED